Adrese Michael Kandahari

Adrese Michael Kandahari

Auto-generated profile, based on publicly available information

Adrese Michael Kandahari

Division of Hematology/Oncology Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington DC USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2021 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
KDKimberley Doucette
Kimberley Doucette
MPMary‐Elizabeth Percival
Mary‐Elizabeth Percival
LWLacey Williams
Lacey Williams
AKAdrese Kandahari
Adrese Kandahari
ATAllison Taylor
Allison Taylor
CLCatherine Lai
Catherine Lai

1 December 2019 in Blood and Lymphatic Cancer: Targets and Therapy
Verified
Journal Article
Open access
PDF file
CLCatherine Lai
Catherine Lai
AKAdrese Michael Kandahari
Adrese Michael Kandahari
CUChaitra Ujjani
Chaitra Ujjani
The arrival of the CD30 directed antibody-drug conjugate, brentuximab vedotin (BV), has altered the approach to patients with classical Hodgkin lymphoma. Since initial approval in 2011, BV has been extensively studied in previously untreated and relapsed/refractory patients. Treatment indications for the antibody-drug conjugate have been expanded from the previously treated population to include maintenance therapy after autologous stem cell transplantation and recently, combination with chemotherapy in newly diagnosed advanced stage patients. This article will review the evolution of BV in classical Hodgkin lymphoma, detailing the studies that led to the approved indications and discussion of recent trials in combination with chemotherapy and immunotherapy.